Screening Libraries
Cat. | Size | Price | Stock | |
L20112 | 1mg/well * 3 Compounds | Inquiry | In stock | Contact Us |
L20112 | 100uL/well (10mM solution) * 3 Compounds | Inquiry | In stock |
manager@chemfaces.com | |
Tel | (0086)-27-8423-7683 |
Shelf Life | (0086)-27-84254680 |
Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
Container | 96 Well Format Sample |
Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
Shelf Life | 24 months (2-8 °) |
Intended Use | For research use only. Not for human use. Not sell to patients |
1. The products in the ChemFaces screening libraries are all from plants. |
2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
Catalog No. | Information |
CFN99716 | Palmitic acid Palmitic acid induces anxiety-like behavior in mice while increasing amygdala-based serotonin metabolism, it induces down-regulation of APOM expression, is mediated via the PPARβ/δ pathway. Palmitic acid induces degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. it also shows in vivo antitumor activity in mice. Palmitic acid is CNS mediated via PKC-theta activation, resulting in reduced insulin activity. |
CFN00085 | Lavendustin A Lavendustin A is a potent tyrosine kinase inhibitor of the epidermal growth factor (EGF) receptor, and an angiogenesis inhibitor. Lavendustin A is also a hyperbolic mixed-type inhibitor with respect to both ATP and the peptide substrate, with a major effect on the binding affinities for both substrates. Lavendustin A at 0.1 nM-1 microM causes a concave-shaped inhibition of the insulin release stimulated by 7 mM glucose, the inhibitory effect can be overcomed by higher concentrations of glucose. Lavendustin A and hormothamnione exhibit cytotoxic effects on tumor cell lines. |
CFN97005 | Sissotrin Sissotrin can impair glucose tolerance. |